Patient characteristics: bax/bcl-2 ratio
| Total no. | 255 |
| Male | 140 |
| Female | 115 |
| No. of patients | |
| Younger than 60 y | 116 |
| Older than 60 y | 139 |
| WBC, × 109/L | |
| Less than 50 | 161 |
| 50-100 | 58 |
| More than 100 | 36 |
| Positive cases (bax/bcl-2 less than 0.3) | 130/255 (51%) |
| CR rate, all patients | 60.2% |
| bax/bcl-2 less than 0.3 | 45% |
| bax/bcl-2 greater than 0.3 | 79% (P = .000 01) |
| Median duration of survival, all patients* | 39 |
| bax/bcl-2 less than 0.3 | 27 (P = .000 01) |
| bax/bcl-2 greater than 0.3 | 53 |
| Median disease free survival, all patients* | 38 |
| bax/bcl-2 less than 0.3 | 24 (P = .019) |
| bax/bcl-2 greater than 0.3 | 48 |
| Total no. | 255 |
| Male | 140 |
| Female | 115 |
| No. of patients | |
| Younger than 60 y | 116 |
| Older than 60 y | 139 |
| WBC, × 109/L | |
| Less than 50 | 161 |
| 50-100 | 58 |
| More than 100 | 36 |
| Positive cases (bax/bcl-2 less than 0.3) | 130/255 (51%) |
| CR rate, all patients | 60.2% |
| bax/bcl-2 less than 0.3 | 45% |
| bax/bcl-2 greater than 0.3 | 79% (P = .000 01) |
| Median duration of survival, all patients* | 39 |
| bax/bcl-2 less than 0.3 | 27 (P = .000 01) |
| bax/bcl-2 greater than 0.3 | 53 |
| Median disease free survival, all patients* | 38 |
| bax/bcl-2 less than 0.3 | 24 (P = .019) |
| bax/bcl-2 greater than 0.3 | 48 |
Survival parameters are expressed in weeks.